Discover the history of GSK using our interactive timeline.
We are a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare.
On March 2, 2015 we completed a 3-part transaction with Novartis which reshapes our business.
We acquired Novartis's vaccines business (excluding influenza vaccines) and combined our Consumer Healthcare businesses to create a new company. By substantially strengthening Vaccines and Consumer Healthcare, we can deliver far-reaching benefits to patients and consumers, and further value to shareholders. In addition, Novartis acquired our marketed Oncology portfolio.
For more information on the 3-part transaction, please visit www.gsk.com.
GSK has a strong presence in biological, pharmaceuticals and vaccines, with a product portfolio that extends across a variety of therapeutic areas and diseases including:
The company is also Canada's leading flu vaccine manufacturer and supplies 50 per cent of Canadian government seasonal flu vaccine purchases.
GSK is designated a Caring Company by Imagine Canada, contributing more than one per cent of pre-tax profits annually through The GlaxoSmithKline Foundation and other channels to initiatives in health, science education and local community organizations.
The $22 million GlaxoSmithKline Pathfinders Fund for Leaders in Canadian Health Science Research was established to help Canada become a world leader in R&D. This initiative encourages health science research and fosters innovation in Canadian medical schools.